Nuchev Limited grew revenue by 12% in FY26, driven by domestic expansion, yet saw margins contract and adjusted EBITDA losses deepen to A$4.6 million. The company’s FY27 focus shifts to margin improvement, operating leverage, and cash conversion.
- 12% revenue growth driven by domestic market expansion
- Adjusted EBITDA loss widens to A$4.6 million
- Gross margin declines 3.7 percentage points to 43.6%
- Non-cash goodwill impairment of A$1.9 million impacts statutory loss
- FY27 priorities include margin recovery and working capital discipline
Revenue Growth Masks Margin and Profitability Challenges
Nuchev Limited (ASX:NUC) posted a 12% increase in FY26 revenue to A$25.7 million, largely propelled by stronger domestic sales that now represent 76% of group revenue. However, beneath the top-line growth lurked a weakening profit picture, with adjusted EBITDA losses expanding to A$4.6 million from a A$3.3 million loss in FY25. Gross margin contracted by 3.7 percentage points to 43.6%, reflecting rising cost of sales outpacing revenue gains.
Domestic Momentum Contrasts with International and Practitioner Setbacks
The company’s domestic brands, notably Oli6, gained traction across grocery and pharmacy channels, supported by portfolio expansion including goat-nutrition products. Meanwhile, international revenue fell nearly 30%, with China and Vietnam markets underperforming due to distributor challenges and regulatory hurdles. The Practitioner health segment, which had shown early promise, softened in the latter half of FY26 amid distributor disruptions and uneven ordering patterns.
Distribution Model Shift Increases Working Capital Intensity
Nuchev’s transition from an agency to a distribution model for key brands such as Brauer, Skin Physics, and Rapid Loss broadened its operational footprint but also increased balance-sheet demands. Receivables nearly doubled and inventory rose 37%, tying up cash in stock and customer debt. Payables surged 185%, reflecting supplier balances growing alongside the expanded operating model. Management highlighted the need to better align inventory and cash flow with confirmed demand to improve working capital efficiency.
Cash Flow and Liquidity Under Pressure Despite Financing Support
Operating cash outflows widened to A$6.6 million, nearly doubling from FY25, driven by the operating loss and investments in working capital. Financing activities, including A$1.9 million in share proceeds and A$3.5 million in borrowings, helped maintain a closing cash balance of A$2.1 million. The company holds unsecured shareholder-backed facilities totalling A$6 million, with A$2.5 million still available. Directors flagged a material uncertainty around going concern, citing sensitivity to revenue growth, margin recovery, and facility drawdowns.
FY27 Strategy Focuses on Margin Improvement and Cash Conversion
Nuchev’s strategic priorities for FY27 centre on scaling its multiple revenue engines; Oli6, Practitioner, Distribution, and Innovation; while improving contribution margins and converting growth into cash flow. The company plans to strengthen domestic momentum, rebuild the Practitioner channel through direct ecommerce and education, and continue expanding its distribution platform. Management emphasised disciplined cost control and tighter inventory management to enhance operating leverage and working capital conversion. No formal earnings guidance was provided, but the company outlined planning assumptions including continued domestic growth and full-year contributions from the expanded Brauer distribution portfolio.
Broader Platform Expansion Sets the Stage, But Execution Risks Remain
FY26 saw Nuchev broaden its nutrition and wellness platform with a wider product range and more integrated routes to market. The shift to a distribution model aims to improve margin capture and brand control, yet also raises complexity and capital intensity. Execution challenges in international and practitioner segments underline ongoing volatility and the need for tighter operational discipline. How effectively Nuchev can convert its expanded scale into sustainable profitability and cash flow will be a key focus for investors in the coming year.
Bottom Line?
Nuchev’s FY26 results show clear domestic growth but underline the challenge of converting scale into profit and cash, with FY27 execution on margin and working capital critical to its turnaround.
Questions in the middle?
- Can Nuchev restore margin momentum while managing increased working capital demands?
- How quickly will the Practitioner and international segments recover from FY26 execution setbacks?
- Will the distribution model shift deliver the expected leverage without further cash strain?